As such, in this study we hypothesized that raltegravir-mediated NLRP3 inhibition may be a major mechanism whereby this integrase inhibitor can protect vascular endothelial cells against ALI-associated damage. The gene discussed is NLRP3; the disease is acute respiratory distress syndrome.